Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RNA-LP Vaccines for Newly Diagnosed pHGG and Adult GBM
NCT04573140Phase 1Recruiting
- Sponsor
- University of Florida
- Start
- Dec 2021
- Primary completion
- Jul 2027
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of RNA-LP vaccine in glioblastoma (GBM) and glioma (2 arms), sponsored by University of Florida. Primary endpoints: Manufacturing feasibility up to 20 weeks, Safety of RNA-LP vaccine and 1 more. Started Dec 2021; status: recruiting.
02
Drugs
RNA-LP vaccine
03
Conditions
glioblastoma (GBM)glioma
Beyond the preview
Go deeper on NCT04573140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04573140.